Paul T Edlefsen1, Peter B Gilbert, Morgane Rolland. 1. Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: The genetic characterization of HIV-1 breakthrough infections in vaccine and placebo recipients offers new ways to assess vaccine efficacy trials. Statistical and sequence analysis methods provide opportunities to mine the mechanisms behind the effect of an HIV vaccine. RECENT FINDINGS: The release of results from two HIV-1 vaccine efficacy trials, Step/HVTN-502 (HIV Vaccine Trials Network-502) and RV144, led to numerous studies in the last 5 years, including efforts to sequence HIV-1 breakthrough infections and compare viral characteristics between the vaccine and placebo groups. Novel genetic and statistical analysis methods uncovered features that distinguished founder viruses isolated from vaccinees from those isolated from placebo recipients, and identified HIV-1 genetic targets of vaccine-induced immune responses. SUMMARY: Studies of HIV-1 breakthrough infections in vaccine efficacy trials can provide an independent confirmation to correlates of risk studies, as they take advantage of vaccine/placebo comparisons, whereas correlates of risk analyses are limited to vaccine recipients. Through the identification of viral determinants impacted by vaccine-mediated host immune responses, sieve analyses can shed light on potential mechanisms of vaccine protection.
PURPOSE OF REVIEW: The genetic characterization of HIV-1 breakthrough infections in vaccine and placebo recipients offers new ways to assess vaccine efficacy trials. Statistical and sequence analysis methods provide opportunities to mine the mechanisms behind the effect of an HIV vaccine. RECENT FINDINGS: The release of results from two HIV-1 vaccine efficacy trials, Step/HVTN-502 (HIV Vaccine Trials Network-502) and RV144, led to numerous studies in the last 5 years, including efforts to sequence HIV-1 breakthrough infections and compare viral characteristics between the vaccine and placebo groups. Novel genetic and statistical analysis methods uncovered features that distinguished founder viruses isolated from vaccinees from those isolated from placebo recipients, and identified HIV-1 genetic targets of vaccine-induced immune responses. SUMMARY: Studies of HIV-1 breakthrough infections in vaccine efficacy trials can provide an independent confirmation to correlates of risk studies, as they take advantage of vaccine/placebo comparisons, whereas correlates of risk analyses are limited to vaccine recipients. Through the identification of viral determinants impacted by vaccine-mediated host immune responses, sieve analyses can shed light on potential mechanisms of vaccine protection.
Authors: B S Graham; M J McElrath; R I Connor; D H Schwartz; G J Gorse; M C Keefer; M J Mulligan; T J Matthews; S M Wolinsky; D C Montefiori; S H Vermund; J S Lambert; L Corey; R B Belshe; R Dolin; P F Wright; B T Korber; M C Wolff; P E Fast Journal: J Infect Dis Date: 1998-02 Impact factor: 5.226
Authors: R I Connor; B T Korber; B S Graham; B H Hahn; D D Ho; B D Walker; A U Neumann; S H Vermund; J Mestecky; S Jackson; E Fenamore; Y Cao; F Gao; S Kalams; K J Kunstman; D McDonald; N McWilliams; A Trkola; J P Moore; S M Wolinsky Journal: J Virol Date: 1998-02 Impact factor: 5.103
Authors: Holly Janes; David P Friedrich; Amy Krambrink; Rebecca J Smith; Esper G Kallas; Helen Horton; Danilo R Casimiro; Mary Carrington; Daniel E Geraghty; Peter B Gilbert; M Juliana McElrath; Nicole Frahm Journal: J Infect Dis Date: 2013-07-21 Impact factor: 5.226
Authors: Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim Journal: N Engl J Med Date: 2009-10-20 Impact factor: 91.245
Authors: M Juliana McElrath; Stephen C De Rosa; Zoe Moodie; Sheri Dubey; Lisa Kierstead; Holly Janes; Olivier D Defawe; Donald K Carter; John Hural; Rama Akondy; Susan P Buchbinder; Michael N Robertson; Devan V Mehrotra; Steven G Self; Lawrence Corey; John W Shiver; Danilo R Casimiro Journal: Lancet Date: 2008-11-13 Impact factor: 79.321
Authors: Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson Journal: Lancet Date: 2008-11-13 Impact factor: 79.321
Authors: Nilu Goonetilleke; Michael K P Liu; Jesus F Salazar-Gonzalez; Guido Ferrari; Elena Giorgi; Vitaly V Ganusov; Brandon F Keele; Gerald H Learn; Emma L Turnbull; Maria G Salazar; Kent J Weinhold; Stephen Moore; Norman Letvin; Barton F Haynes; Myron S Cohen; Peter Hraber; Tanmoy Bhattacharya; Persephone Borrow; Alan S Perelson; Beatrice H Hahn; George M Shaw; Bette T Korber; Andrew J McMichael Journal: J Exp Med Date: 2009-06-01 Impact factor: 14.307
Authors: Andrew J Gartland; Sue Li; John McNevin; Georgia D Tomaras; Raphael Gottardo; Holly Janes; Youyi Fong; Daryl Morris; Daniel E Geraghty; Gustavo H Kijak; Paul T Edlefsen; Nicole Frahm; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Allan C deCamp; Craig A Magaret; Hasan Ahmed; Jodie P Goodridge; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; John Sidney; Alessandro Sette; Susan Zolla-Pazner; David Montefiori; M Juliana McElrath; James I Mullins; Jerome H Kim; Peter B Gilbert; Tomer Hertz Journal: J Virol Date: 2014-05-14 Impact factor: 5.103
Authors: T Hertz; M G Logan; M Rolland; C A Magaret; C Rademeyer; A Fiore-Gartland; P T Edlefsen; A DeCamp; H Ahmed; N Ngandu; B B Larsen; N Frahm; J Marais; R Thebus; D Geraghty; J Hural; L Corey; J Kublin; G Gray; M J McElrath; J I Mullins; P B Gilbert; C Williamson Journal: Vaccine Date: 2016-10-15 Impact factor: 3.641
Authors: Kalpana Dommaraju; Gustavo Kijak; Jonathan M Carlson; Brendan B Larsen; Sodsai Tovanabutra; Dan E Geraghty; Wenjie Deng; Brandon S Maust; Paul T Edlefsen; Eric Sanders-Buell; Silvia Ratto-Kim; Mark S deSouza; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttihum; Jaranit Kaewkungwal; Robert J O'Connell; Merlin L Robb; Nelson L Michael; James I Mullins; Jerome H Kim; Morgane Rolland Journal: PLoS One Date: 2014-10-28 Impact factor: 3.240
Authors: Sarah Sterrett; Gerald H Learn; Paul T Edlefsen; Barton F Haynes; Beatrice H Hahn; George M Shaw; Katharine J Bar Journal: Open Forum Infect Dis Date: 2014-08-14 Impact factor: 3.835
Authors: Hui Li; Mark B Stoddard; Shuyi Wang; Elena E Giorgi; Lily M Blair; Gerald H Learn; Beatrice H Hahn; Harvey J Alter; Michael P Busch; Daniel S Fierer; Ruy M Ribeiro; Alan S Perelson; Tanmoy Bhattacharya; George M Shaw Journal: J Virol Date: 2015-10-14 Impact factor: 5.103
Authors: Holly Janes; Joshua T Herbeck; Sodsai Tovanabutra; Rasmi Thomas; Nicole Frahm; Ann Duerr; John Hural; Lawrence Corey; Steve G Self; Susan P Buchbinder; M Juliana McElrath; Robert J O'Connell; Robert M Paris; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttihum; Jaranit Kaewkungwal; Merlin L Robb; Nelson L Michael; James I Mullins; Jerome H Kim; Peter B Gilbert; Morgane Rolland Journal: Nat Med Date: 2015-08-31 Impact factor: 53.440